Search Results for "Colchicine And Rivaroxaban"

00:15 EDT 24th August 2016 | BioPortfolio

Matching Channels


Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Rivaroxaban in the Real World

A large Phase IV registry study shows that rivaroxaban is associated with a very low incidence of major bleeding, death, or stroke. Also, adherence to therapy was much higher than observed in other st...

BRIEF-Hikma says U.S. Court of Appeals upholds regulatory approval of colchicine

* Fda's regulatory approval of hikma's colchicine 0.6 mg capsule product was upheld.

Rivaroxaban Saves Hospitals Money for VTE Admissions: Study

U.S. hospitals save money when they use the novel oral anticoagulant rivaroxaban instead of warfarin to treat patients with venous thromboembolism (VTE), a new analysis finds. Reuters Health Informa...

BRIEF-Bayer says patent term for Rivaroxaban extended in United States

* Says patent term for Rivaroxaban extended in us Further company coverage:

Management of Oral Anticoagulation in Atrial Fibrillation Patients with Worsening Renal Function

Approximately 25% of atrial fibrillation patients in a large trial comparing rivaroxaban to warfarin developed worsening renal failure during follow-up. Those treated with rivaroxaban had less embolic...

Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever – a randomized controlled noninferiority trial

In this study, we examined the efficacy and safety of a once-daily dosage schema of colchicine compared with a twice-daily dosage schema in pediatric patients with familial Mediterranean fever (FMF).

Major bleeding risk low in real-world study of high-risk users of rivaroxaban

CHICAGO — A postmarketing study of users with nonvalvular atrial fibrillation taking rivaroxaban confirms that the real-world risk for major bleeding was extremely low, even in high-risk patients, r...

EULAR releases 2016 gout management guidelines

In a recently published report, the EULAR has updated its 2006 gout management recommendations with 11 key points.Colchicine or NSAIDs were recommended for the treatment of flares alone or in combinat...

Matching PubMed Articles

Colchicine for prevention of cardiovascular events.

Colchicine is an anti-inflammatory drug that is used for a wide range of inflammatory diseases. Cardiovascular disease also has an inflammatory component but the effects of colchicine on cardiovascula...

A high performance thin layer chromatographic method for the estimation of colchicine in different formulations.

Colchicine is a main alkaloid present in bitter and sweet variety of colchicum (Colchicum luteum Baker), which have been reported to possess anti-rheumatic, anti-gout, and anticancer potential. Colchi...

Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

The aims of this study were to investigate the effects of rivaroxaban on routine coagulation assays using our local, widely available, reagents and to study the relationship between sensitive coagulat...

Exploring the Origin of Differential Binding Affinities of Human Tubulin Isotypes αβII, αβIII and αβIV for DAMA-Colchicine Using Homology Modelling, Molecular Docking and Molecular Dynamics Simulations.

Tubulin isotypes are found to play an important role in regulating microtubule dynamics. The isotype composition is also thought to contribute in the development of drug resistance as tubulin isotypes...

Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.

Rivaroxaban (Xarelto) does not require routine coagulation monitoring; however, in certain clinical situations (overdose, drug accumulation, urgent surgery) measurement of its plasma concentration is ...

Search Whole site using Google

Quick Search
Advertisement Advertisement